RAS LSS Consulting’s Post

View organization page for RAS LSS Consulting, graphic

4,711 followers

🚀 Exciting News from Avalo Therapeutics, Inc. (Nasdaq: AVTX) 🚀   #Avalo is investing over $22 million in stock and cash to acquire #AlmataBio for the anti-IL-1β monoclonal antibody AVTX-009, which originated from Eli Lilly.   AVTX-009 is considered a significant asset by Avalo, with the belief that it has the potential to be a leading treatment for hidradenitis suppurativa (HS) due to its target specificity, half-life, and potency. The company views HS as a lucrative commercial opportunity and aims for AVTX-009 to be best-in-class and best-in-indication, offering strong efficacy and convenient dosing.   Avalo's focus remains on developing AVTX-009 for HS, with topline results from a planned Phase 2 trial expected in 2026. Stay tuned for updates as Avalo continues its mission to revolutionize treatment for inflammatory diseases! 💊✨ #AvaloTherapeutics #Innovation #Biotech #HealthcareInvestment   Detailed News: https://lnkd.in/dKeTcDXK

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million | BioSpace

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million | BioSpace

biospace.com

To view or add a comment, sign in

Explore topics